Faron Pharmaceuticals Oy (FARN) — Cash Flow-to-Debt Ratio
Faron Pharmaceuticals Oy (FARN) has a Cash Flow-to-Debt Ratio of 0.00x as of June 2025, meaning its operating cash flow of GBX-5.21K could theoretically repay 0% of its total liabilities (GBX32.45 Million) in one year. Explore Faron Pharmaceuticals Oy strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Faron Pharmaceuticals Oy Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Faron Pharmaceuticals Oy across 13 annual periods. Also explore how large is Faron Pharmaceuticals Oy's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Faron Pharmaceuticals Oy (2012–2024)
Year-by-year debt coverage analysis for Faron Pharmaceuticals Oy. For market capitalisation and broader financial context, see Faron Pharmaceuticals Oy market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.03x | GBX-22.97 Million | GBX22.28 Million | ▼ -9.9% |
| 2023 | -0.94x | GBX-23.81 Million | GBX25.38 Million | ▲ +7.2% |
| 2022 | -1.01x | GBX-22.99 Million | GBX22.75 Million | ▲ +53.3% |
| 2021 | -2.16x | GBX-22.22 Million | GBX10.26 Million | ▼ -26.5% |
| 2020 | -1.71x | GBX-17.48 Million | GBX10.22 Million | ▼ -27.7% |
| 2019 | -1.34x | GBX-11.52 Million | GBX8.60 Million | ▼ -49734.5% |
| 2018 | 0.00x | GBX-20.52K | GBX7.63 Million | ▲ +99.9% |
| 2017 | -1.81x | GBX-18.36 Million | GBX10.14 Million | ▼ -37.2% |
| 2016 | -1.32x | GBX-8.45 Million | GBX6.40 Million | ▲ +32.7% |
| 2015 | -1.96x | GBX-7.15 Million | GBX3.64 Million | ▼ -1590.8% |
| 2014 | -0.12x | GBX-389.00K | GBX3.35 Million | ▲ +51.9% |
| 2013 | -0.24x | GBX-768.00K | GBX3.19 Million | ▲ +70.5% |
| 2012 | -0.82x | GBX-2.27 Million | GBX2.77 Million | — |